Results 231 to 240 of about 15,170 (273)

Biomaterial‐Integrated Electroporation for Therapeutic Delivery: From Gene Editing to Tumor Ablation and Immune Modulation

Small, EarlyView.
Biomaterial‐integrated electroporation establishes a programmable therapeutic interface that coordinates electric‐field modulation, transient or irreversible membrane permeabilization, cargo stabilization, and immune remodeling. This Review highlights how nanocarriers, hydrogels, and bioelectronic interfaces expand electroporation from conventional ...
Binbin Ji, Zhuozhuo Wu, Yuyue Jiang, Xiaoyu Liu, Jingfeng Li, Fengkuo Xu, Chaojie Li, Qungang Shan, Ziyin Wang, Junhao Wang, Wei Huang, Yaping Zhuang, Wenguo Cui, Zhongmin Wang   +13 more
wiley   +1 more source

TROP2-targeting antibody-drug conjugates in breast cancer and ovarian carcinoma: therapeutic advances and resistance mechanisms. [PDF]

Cancer Drug Resist
Eroles P, Dawid de Vera MT, Lago V.
europepmc   +1 more source

3D‐Printed Milli‐Fluidic Mixing‐Extrusion Platform for Continuous, High‐Throughput LNP Production

Small, EarlyView.
We report a continuous high‐throughput production of lipid nanoparticles (LNPs) by integrating a reusable 3D‐printed milli‐fluidic split‐and‐recombine mixer with inline membrane extrusion. The 3D architecture enables rapid early‐stage mixing, reducing clogging and fouling, while inline extrusion further refines the as‐formed LNPs, improving uniformity,
Leekang Jeon, Seeun Kim, Hanjin Seo, Hyun Su Lee, Gi‐Su Na, Gi‐Ra Yi, Hyomin Lee   +6 more
wiley   +1 more source

Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer. [PDF]

Breast
Liu X, Yin S, Li X, Nie J.
europepmc   +1 more source

Antibody-drug conjugates in cancer treatment: from molecular design to clinical implementation. [PDF]

Lancet Reg Health Eur
Mansinho A, Albuquerque J, Barigazzi C, Calvo E.   +3 more
europepmc   +1 more source

Immuno-cytotoxic convergence: integrating antibody‒drug conjugates and immunofusion proteins to overcome resistance in gastrointestinal cancers. [PDF]

J Hematol Oncol
Wu S, Cui R, Zhao K, Yang Z, Yi Z, Cao W, Ye L.   +6 more
europepmc   +1 more source

A Novel Dual-Payload ADC Platform Integrating Exatecan and Triptolide to Enhance Antitumor Efficacy and Overcome Resistance. [PDF]

Mol Cancer Ther
Ren P, Guan M, Tang J, Yin S, Qi L, Yue J, Li Z, Fan X, Lei G, Zuo T, Chen J, Xu Y, Ke X, Zhao Y.   +13 more
europepmc   +1 more source

Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology. [PDF]

Front Bioeng Biotechnol
Wang H, Yan X, Xia C, Chen D, Pan B, Zhang Y, Zhang Q.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Beyond cytotoxic potency: disposition features required to design ADC payload

Xenobiotica
1. Antibody-drug conjugates (ADCs) have demonstrated impressive clinical usefulness in treating several types of cancer, with the notion of widening of the therapeutic index of the cytotoxic payload through the minimisation of the systemic toxicity. Therefore, choosing the most appropriate payload molecule is a particularly important part of the early ...
Larry C Wienkers
exaly   +3 more sources

Abstract 1646: Highly cytotoxic, completely human constructs targeting HER2 and containing the immuno-oncology payload granzyme B [PDF]

Cancer Research, 2017
Abstract Recent immunotherapeutic approaches designed to augment T- and B-cell mediated killing of tumor cells has met with clinical success suggesting that immuno-oncology (IO) approaches have tremendous potential for treatment in a broad spectrum of tumor types.
Lawrence H. Cheung, Yunli Zhao, Khalid A. Mohamedali, Ana Alvarez-Cienfuegos, Walter N. Hittelman, Michael G. Rosenblum   +5 more
openaire   +2 more sources